57岁男性COVID-19肺炎需VV-ECMO期间白细胞快速升高
一名57岁男性因COVID-19肺炎致低氧性呼吸衰竭,接受有创通气及静脉-静脉体外膜氧合(VV-ECMO)支持。在ECMO第13至17天,白细胞计数从17,500升至47,000 cells/μL,同期出现液体难治性休克需多种血管加压药,并开始广谱抗微生物治疗(含抗真菌及抗蠕虫)。
要点
- COVID-19肺炎VV-ECMO支持者可出现白细胞快速升高,需警惕继发感染或炎症反应。
- 白细胞升高期间可并发液体难治性休克,需血管加压药支持。
- 广谱抗微生物治疗需覆盖真菌及寄生虫可能,但需结合临床评估。
核心结论
- COVID-19肺炎接受VV-ECMO支持的患者在ECMO第13至17天出现白细胞从17,500升至47,000 cells/μL,并伴液体难治性休克。
研究设计与样本
- 单例病例报告:57岁男性,因COVID-19肺炎低氧性呼吸衰竭插管并接受VV-ECMO后转至作者机构。
主要发现
- ECMO第13至17天,白细胞计数从17,500 cells/μL升至47,000 cells/μL。
- 同期出现液体难治性休克,需多种血管加压药,白细胞30,000 cells/μL时接受应激剂量氢化可的松。
- 患者始终无发热,启动包括抗真菌及抗蠕虫的广谱抗微生物治疗。
关键数值与推荐
- 静脉肝素抗凝,抗Xa因子目标0.1至0.3 international unit/mL。
- 白细胞30,000 cells/μL时给予应激剂量氢化可的松。
临床怎么用
- VV-ECMO支持的COVID-19肺炎患者出现白细胞快速升高时,应评估继发感染及炎症反应并考虑广谱抗微生物覆盖。
局限性
- 单例病例报告,结论外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 57-year-old man who had been intubated and placed on venovenous extracorporeal membrane oxygenation for hypoxemic respiratory failure due to COVID-19 pneumonia was transferred to our facility. He underwent anticoagulation with IV heparin titrated to an anti-Factor Xa goal of 0.1 to 0.3 international unit/mL. Over extracorporeal membrane oxygenation days 13 to 17, his WBC count rose from 17,500 to 47,000 cells/μL. He simultaneously experienced the development of fluid-refractory shock that required multiple vasopressors and received stress-dose hydrocortisone when his WBC was 30,000 cells/μL. He remained afebrile and was started on broad-spectrum antimicrobials that included antifungal and anthelminthic therapy.
引用
- Krieger JA, Wixon-Genack JR, Mandell SP, et al. A 57-Year-Old Man With COVID-19 Pneumonia Who Required Venovenous Extracorporeal Life Support With a Rapidly Escalating WBC Count. Chest. 2021. PMID: 34366043. doi:10.1016/j.chest.2021.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。